



Correction to: Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canaglifozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting

Sara Stafford¹ · Peter G. Bech² · Adam Fridhammar³ · Nino Miresashvili⁴ · Andreas Nilsson³ · Michael Willis³ · Aiden Liu²

Published online: 20 April 2022
© The Author(s) 2022

Correction to: Applied Health Economics and Health Policy
<https://doi.org/10.1007/s40258-022-00726-z>

The article “Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canaglifozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting”, written by Sara Stafford, Peter G. Bech, Adam Fridhammar, Nino Miresashvili, Andreas Nilsson, Michael Willis and Aiden Liu was originally published electronically on the publisher’s internet portal on 28th March 2022 without open access.

With the author(s)’ decision to opt for Open Choice the copyright of the article changed on 1st April 2022 to © The Author(s) 2022 and the article is forthwith distributed under a Creative Commons Attribution-Noncommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third-party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included

in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

The original article has been corrected.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

The original article can be found online at <https://doi.org/10.1007/s40258-022-00726-z>.

✉ Sara Stafford
sara.stafford@fraserhealth.ca

¹ Fraser Health Division of Endocrinology, 902-13737 96th Avenue, Surrey, BC V3V 0C6, Canada

² Novo Nordisk Canada Inc., 2476 Argentia Rd, Mississauga, ON L5N 6M1, Canada

³ The Swedish Institute for Health Economics, Box 2127, 220 02 Lund, Sweden

⁴ Novo Nordisk A/S, Vandtårnsvej 108, 2860 Søborg, Denmark